People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other Health Care, Healthtech, Biotechnology, AI / ML
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NeuroPace Inc | — | Other Health Care | Series C | $208.6M | $1.5B | 2011 |
| Astute Medical, Inc. | — | Healthtech | Series C | $167.8M | $1.1B | 2010 |
| Cell Biosciences Inc | — | Biotechnology | Series B | $62.3M | $516.0M | 2009 |
| Ocunexus Therapeutics, Inc. | — | Biotechnology | Series B | $53.2M | $292.3M | 2011 |
| Applied Proteomics, Inc. | — | Biotechnology | Series B | $50.4M | $1.1B | 2013 |
| InflammX Therapeutics, Inc. | — | Biotechnology | Series A | $15.4M | $156.2M | 2020 |
| Helixis Inc | — | Biotechnology | Series A | $12.7M | $265.1M | 2009 |
| Carrot Labs Inc | — | AI / ML | Pre-Seed | $1.2M | $1.9M | 2024 |
James Blair at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Blair on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brian Levy | 2 | 8 |
| David Pool | 2 | 4 |
| Peter Thompson | 1 | 16 |
| Rishi Gupta | 1 | 12 |
| Nael Kassar | 1 | 11 |
| Jonathan Silverstein | 1 | 10 |
| Greg Garfield | 1 | 8 |
| James C. Blair | 1 | 8 |
| David Barker | 1 | 7 |
| David Fischell | 1 | 6 |
| Renee Ryan | 1 | 6 |
| Benjamin Pless | 1 | 5 |
| David Douglass | 1 | 5 |
| Lynne Rollins | 1 | 5 |
| Frank Fischer | 1 | 5 |
| Joseph Lacob | 1 | 4 |
| Brad Vale | 1 | 4 |
| Tom Rodgers | 1 | 4 |
| James Woody | 1 | 4 |
| Evan Norton | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.